HeartFlow

HTFLPre-clinical

San Francisco, United StatesFounded 2010heartflow.com

HeartFlow's mission is to transform coronary artery disease (CAD) from the leading cause of death into a manageable condition for life. The company leverages a proprietary AI-powered platform to analyze CCTA scans, generating non-invasive fractional flow reserve (FFRCT) measurements, plaque quantification, and anatomical roadmaps to guide patient care. With over 600,000 patients treated, 1,800+ institutions using its technology, and a robust clinical evidence base of 600+ peer-reviewed publications, HeartFlow is establishing itself as a leader in precision cardiovascular diagnostics. The company is headquartered in San Francisco, California, and operates globally.

Market Cap

$2.2B

Founded

2010

HTFL · Stock Price

USD 26.023.97 (-13.24%)

Historical price data

AI Company Overview

Technology Platform

An AI-powered software platform that analyzes standard coronary CT angiograms (CCTA) to create personalized 3D models of the heart, providing non-invasive fractional flow reserve (FFRCT) measurements, plaque quantification, and anatomical roadmaps.

Pipeline Snapshot

3 drugs in pipeline

Drug	Indication	Stage
Evolocumab	Coronary Artery Disease	Approved
Rosuvastatin 40mg + Placebo	Coronary Artery Disease	Pre-clinical
High intensity lipid lowering	Coronary Artery Disease	Pre-clinical

Opportunities

Significant growth opportunity driven by global guideline shifts recommending CCTA as a first-line test for stable chest pain, creating a large addressable market.

The integrated HeartFlow One platform and plaque analysis tools enable a recurring software revenue model within health systems for longitudinal disease management.

Expansion of reimbursement codes and coverage, particularly in the U.S.

and through systems like NHS England, provides a clear pathway for increased adoption.

Risk Factors

Faces intense competition in the AI-powered cardiac imaging space, especially for plaque analysis.

Growth is dependent on the adoption rate of CCTA and changing entrenched clinical workflows.

As a private company, it may face future capital needs for scaling and competition, and remains subject to ongoing regulatory requirements for its software-as-a-medical-device.

Competitive Landscape

Competes directly with other AI-based CT-FFR and plaque analysis software vendors (e.g., Siemens, Canon, Cleerly, Elucid) and indirectly with the entire legacy stress testing ecosystem. HeartFlow's key differentiators are its first-mover advantage in FFRCT, extensive clinical validation (600+ publications), integrated platform approach, and established reimbursement footprint.

Publications

Patents

Pipeline